A citation-based method for searching scientific literature

Estelamari Rodriquez, Susan M Domchek. Semin Oncol 2007
Times Cited: 6







List of co-cited articles
14 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
S A Narod, J S Brunet, P Ghadirian, M Robson, K Heimdal, S L Neuhausen, D Stoppa-Lyonnet, C Lerman, B Pasini, P de los Rios,[...]. Lancet 2000
385
50

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
706
50

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
50

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Bernadette A M Heemskerk-Gerritsen, Cecile T M Brekelmans, Marian B E Menke-Pluymers, Albert N van Geel, Madeleine M A Tilanus-Linthorst, Carina C M Bartels, Murly Tan, Hanne E J Meijers-Heijboer, Jan G M Klijn, Caroline Seynaeve. Ann Surg Oncol 2007
85
33



Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Susan M Domchek, Tara M Friebel, Susan L Neuhausen, Theresa Wagner, Gareth Evans, Claudine Isaacs, Judy E Garber, Mary B Daly, Rosalind Eeles, Ellen Matloff,[...]. Lancet Oncol 2006
211
33

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
33

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
L C Hartmann, T A Sellers, D J Schaid, T S Frank, C L Soderberg, D L Sitta, M H Frost, C S Grant, J H Donohue, J E Woods,[...]. J Natl Cancer Inst 2001
478
33

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
33

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
33

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Tom Walsh, Silvia Casadei, Kathryn Hale Coats, Elizabeth Swisher, Sunday M Stray, Jake Higgins, Kevin C Roach, Jessica Mandell, Ming K Lee, Sona Ciernikova,[...]. JAMA 2006
440
33

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
H Meijers-Heijboer, B van Geel, W L van Putten, S C Henzen-Logmans, C Seynaeve, M B Menke-Pluymers, C C Bartels, L C Verhoog, A M van den Ouweland, M F Niermeijer,[...]. N Engl J Med 2001
632
33



Counterpoint: the case for immediate active treatment.
Stacy Loeb, William J Catalona. J Natl Compr Canc Netw 2007
1
100

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Stephanie R Land, D Lawrence Wickerham, Joseph P Costantino, Marcie W Ritter, Victor G Vogel, Myoungkeun Lee, Eduardo R Pajon, James L Wade, Shaker Dakhil, James B Lockhart,[...]. JAMA 2006
167
16

Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort.
Adriano Decarli, Stefano Calza, Giovanna Masala, Claudia Specchia, Domenico Palli, Mitchell H Gail. J Natl Cancer Inst 2006
70
16



Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
16

Diet and breast cancer risk reduction.
Eleni Linos, Walter C Willett. J Natl Compr Canc Netw 2007
18
16


Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Elizabeth Barrett-Connor, Lori Mosca, Peter Collins, Mary Jane Geiger, Deborah Grady, Marcel Kornitzer, Michelle A McNabb, Nanette K Wenger. N Engl J Med 2006
668
16


Screening for breast cancer with mammography.
P C Gøtzsche, M Nielsen. Cochrane Database Syst Rev 2006
169
16


Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
493
16

Molecular determinants of tissue selectivity in estrogen receptor modulators.
T A Grese, J P Sluka, H U Bryant, G J Cullinan, A L Glasebrook, C D Jones, K Matsumoto, A D Palkowitz, M Sato, J D Termine,[...]. Proc Natl Acad Sci U S A 1997
210
16

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
16

Women's views on chemoprevention of breast cancer: qualitative study.
R Heisey, N Pimlott, M Clemons, S Cummings, N Drummond. Can Fam Physician 2006
42
16

Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives.
David K Espey, Xiao-Cheng Wu, Judith Swan, Charles Wiggins, Melissa A Jim, Elizabeth Ward, Phyllis A Wingo, Holly L Howe, Lynn A G Ries, Barry A Miller,[...]. Cancer 2007
416
16

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S R Cummings, S Eckert, K A Krueger, D Grady, T J Powles, J A Cauley, L Norton, T Nickelsen, N H Bjarnason, M Morrow,[...]. JAMA 1999
16

Breast cancer risk reduction.
Therese B Bevers, Deborah K Armstrong, Banu Arun, Robert W Carlson, Kenneth H Cowan, Mary B Daly, Irvin Fleming, Judy E Garber, Mary Gemignani, William J Gradishar,[...]. J Natl Compr Canc Netw 2007
6
16

Cancer statistics, 2007.
Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, Michael J Thun. CA Cancer J Clin 2007
16


Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
T Powles, R Eeles, S Ashley, D Easton, J Chang, M Dowsett, A Tidy, J Viggers, J Davey. Lancet 1998
640
16

Molecular basis of agonism and antagonism in the oestrogen receptor.
A M Brzozowski, A C Pike, Z Dauter, R E Hubbard, T Bonn, O Engström, L Ohman, G L Greene, J A Gustafsson, M Carlquist. Nature 1997
16

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
16

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Silvana Martino, Jane A Cauley, Elizabeth Barrett-Connor, Trevor J Powles, John Mershon, Damon Disch, Roberta J Secrest, Steven R Cummings. J Natl Cancer Inst 2004
435
16

The role of robotic surgery in gynecology.
Arnold P Advincula, Arleen Song. Curr Opin Obstet Gynecol 2007
112
16

RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference.
J Etzler, A Peyrl, A Zatkova, H-U Schildhaus, A Ficek, S Merkelbach-Bruse, C P Kratz, A Attarbaschi, J A Hainfellner, S Yao,[...]. Hum Mutat 2008
55
16

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
James Witham, Melanie R Valenti, Alexis K De-Haven-Brandon, Susanne Vidot, Suzanne A Eccles, Stan B Kaye, Alan Richardson. Clin Cancer Res 2007
85
16

Defining social support systems for women with breast cancer.
Jennifer S Gass, Sherry Weitzen, Melissa Clark, Don S Dizon. Am J Surg 2007
7
16

Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Amelia Buffone, Carlo Capalbo, Enrico Ricevuto, Tina Sidoni, Laura Ottini, Mario Falchetti, Enrico Cortesi, Paolo Marchetti, Giovanni Scambia, Silverio Tomao,[...]. Breast Cancer Res Treat 2007
24
16


Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Erin J Aiello, Diana S M Buist, Edward H Wagner, Leah Tuzzio, Sarah M Greene, Lois E Lamerato, Terry S Field, Lisa J Herrinton, Reina Haque, Gene Hart,[...]. Breast Cancer Res Treat 2008
29
16

Continent ileocolonic urinary diversion (Rome pouch) for gynecologic malignancies: technique and feasibility.
Pierluigi Benedetti Panici, Roberto Angioli, Francesco Plotti, Ludovico Muzii, Marzio Angelo Zullo, Natalina Manci, Innocenza Palaia, Michele Galluci. Gynecol Oncol 2007
7
16

Origins of breast cancer subtypes and therapeutic implications.
Andrew H Sims, Anthony Howell, Sacha J Howell, Robert B Clarke. Nat Clin Pract Oncol 2007
98
16

Vaccine immunotherapy in breast cancer treatment: promising, but still early.
Giuseppe Curigliano, Gianluca Spitaleri, Manuela Dettori, Marzia Locatelli, Eloise Scarano, Aron Goldhirsch. Expert Rev Anticancer Ther 2007
31
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.